Table 1. Sample characteristics Patient... | American Society of Hematology

Table 1.

Sample characteristics

Patient	Isotype	Level of IgM in patient, mg/dL	Biopsy, % bone marrow infiltration	Prior therapy	Cells inoculated, × 10⁶	Weeks to detection of IgM	Level of IgM in mouse,^*μg/mL	Level of light chain in mouse,^*μg/mL
1	IgM κ	1240	90	RTX, THAL	5	4	1.8	Negative
2	IgM κ	6130	60	Prednisone	5	16	10	Negative
3	IgM κ	4830	50	Fl, RTX	5	6	0.6	NA
4	IgM κ	1430	70	THAL, DEX	5	28	2.6	0.7
5	IgM λ	2590	60	RTX	10	4	1.5	Negative
6	IgM κ	2390	70-80	None	10	5	2.6	NA
7	IgM, κ	7630	90	None	2	13	0.4	NA
8	IgM,κ	NA	NA	None	2	20	0.2	0.4
9†	IgM κ	4970	95	CVP, RTX	2	7	8.4	0.4
10†	IgM,κ	2340	50	None	2	20	1.8	NA

Patient	Isotype	Level of IgM in patient, mg/dL	Biopsy, % bone marrow infiltration	Prior therapy	Cells inoculated, × 10⁶	Weeks to detection of IgM	Level of IgM in mouse,^*μg/mL	Level of light chain in mouse,^*μg/mL
1	IgM κ	1240	90	RTX, THAL	5	4	1.8	Negative
2	IgM κ	6130	60	Prednisone	5	16	10	Negative
3	IgM κ	4830	50	Fl, RTX	5	6	0.6	NA
4	IgM κ	1430	70	THAL, DEX	5	28	2.6	0.7
5	IgM λ	2590	60	RTX	10	4	1.5	Negative
6	IgM κ	2390	70-80	None	10	5	2.6	NA
7	IgM, κ	7630	90	None	2	13	0.4	NA
8	IgM,κ	NA	NA	None	2	20	0.2	0.4
9†	IgM κ	4970	95	CVP, RTX	2	7	8.4	0.4
10†	IgM,κ	2340	50	None	2	20	1.8	NA

RTX indicates rituximab; THAL, thalidomide; Fl, fludarabine; NA, not available; DEX, dexamethasone; CVP, cyclophosphamide, vincristine, and prednisone.

At time of first IgM detection.

†

In these cases, BM cells were CD19-immunomagnetically sorted before mice inoculation into human bone implant.

View Large

This Feature Is Available To Subscribers Only